Leptomeningeal metastases (LM) remain one of the most challenging complications in neuro-oncology. At Plus Therapeutics, we are committed to changing that.
Our ongoing ReSPECT-LM dose-optimization trial is currently evaluating the optimal treatment regimen for REYOBIQ™ (rhenium Re186 obisbemeda) in patients with LM. This innovative radiotherapeutic approach aims to offer new hope to patients facing this aggressive central nervous system (CNS) disease.
In a recent article by Sabrina Serani in Targeted Oncology, Plus Therapeutics’ President and CEO, Marc Hedrick, M.D., shared insight into the trial’s goals and the importance of advancing LM treatment options:
“Our goal is to develop a therapy that is not only effective, but truly practical and accessible for patients suffering from this devastating condition.”
With support from a $17.6 million award from the Cancer Prevention and Research Institute of Texas (CPRIT), the ReSPECT-LM study is part of our broader effort to develop targeted radiotherapeutics that address critical unmet needs in oncology.
To learn more about this groundbreaking clinical trial, visit:
respect-trials.com/lm
#PSTV #LeptomeningealMetastases #REYOBIQ #Radiotherapeutic #Radiotherapy #NeuroOncology #ClinicalTrials #Radiotherapeutics #CNSCancers #TargetedOncology #ReSPECTLM #CancerResearch #PrecisionMedicine
Recent Comments